Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the fourth-largest manufacturer of specialty pharmaceuticals in the world, with worldwide revenues of more than US$4 billion. 4.5 billion. It is supported by over 40 production facilities that offer quality, affordable medications trusted by health professionals and patients in over 100 countries worldwide.
Diversified Specialty and Generics Portfolio
They make and distribute many different pharmaceutical formulations that cover a broad spectrum of acute and chronic treatments. This includes generics, brand specialties, generics, or difficult-to-make products that require a lot of technology, such as over-the-counter (OTC) antiretroviral (ARVs) and active pharmaceutical ingredients (APIs) as well as intermediates. Their vast collection of over 2000 high-quality molecules includes various dosage forms, such as capsules, tablet injectable, inhalers, creams, ointments, and liquids.
Each year, they sell more than 30 billion doses that deal with cardiology, neuro-psychiatry, gastroenterology anti-infective, diabetes, dermatology, oncology, ophthalmology, nephrology, urology, and respiratory as other areas.
Driven by Innovation
The first Indian pharmaceutical corporations to recognize and appreciate the value of investing in research, they put up to 75% of their worldwide profits into Research and Development (R&D) each year.
Their strength lies in their ability to create technology-driven products and generics with their dedicated teams working on formulations, process chemicals, and the development of analytical techniques.
Their capabilities go beyond creating products such as liposomal ones, Inhalers, lyophilized injectable, nasal sprays, and dose forms controlled in a release.
Their R&D is overseen by a team comprised of around 2000 experts.
Beginning with its humble beginnings of the year 1983, Sun Pharma has grown to become one of the biggest generic pharmaceutical companies in the world. Sun Pharma is the biggest manufacturer of pharmaceuticals in India.
In the US In the US, they are among the top 10 pharmaceutical companies that are generic and are ranked second in prescriptions in the market for generic dermatology.
They are the most significant Indian company operating in emerging markets and have a presence in more than 80 countries. Brazil, Mexico, Russia, Romania, and South Africa are their most important emerging markets.
They are found in all the major markets in Western Europe, Canada, Australia, New Zealand, Japan, China, and other countries.
They are present in markets that have not been developed as well as the developing world allows their teams to cross-sell and create brands quickly.